Cipro, Levaquin & Avelox

Fluoroquinolones are the most widely used antibiotics. About 33 million Americans take the extremely strong medicine to kill bacterial infections each year. The FDA warns that fluoroquinolones, such as Cipro (ciprofloxacin), Avelox (moxifloxacin) and Levaquin (levofloxacin), can cause disabling and potentially irreversible side effects. The drugs' labels include a black box warning — the FDA's strongest warning — for tendon problems and permanent nerve damage. Patients must understand the approved uses, ingredients and risks associated with fluoroquinolones before deciding to take these potentially dangerous drugs.

*Please seek the advice of a medical professional before discontinuing the use of this drug.

Cipro, Levaquin and Avelox Fluoroquinolone Pills

Used to Treat: Certain bacterial infections

Interactions: Antacids, sucralfate, metal cations, multivitamins, warfarin, antidiabetic agents, non-steroidal anti-inflammatory drugs, theophylline, cyclosporine, digoxin, probenecid and cimetidine

Active Ingredients: Ciprofloxacin hydrochloride (Cipro), levofloxacin (Levaquin) and moxifloxacin hydrochloride (Avelox)

Treatment Duration: Seven to 21 days

FDA Approval Status: Cipro-1987; Levaquin-1996; Avelox-1999

View Lawsuit Information

Fluoroquinolones such as Cipro, Levaquin & Avelox are intended to kill or stop the growth of bacteria. This family of antibiotics was first discovered in the 1960s, but it wasn’t until the late 1980s that Cipro and other modern fluoroquinolones first hit the market. At the time, doctors primarily prescribed them to treat urinary tract infections. Since then, they have become the go-to antibiotic for many infections.

These drugs are potent and are approved for the treatment or prevention of serious bacterial infections including anthrax, plague and bacterial pneumonia.

Other approved uses include the treatment of:

  • Skin and skin structure infections
  • Bone and joint infections
  • Complicated intra-abdominal infections
  • Infectious diarrhea
  • Typhoid fever (enteric fever)
  • Uncomplicated cervical and urethral gonorrhea
  • Chronic bacterial prostatitis
  • Lower respiratory tract infections
  • Urinary tract infections
  • Acute uncomplicated cystitis
  • Acute bacterial sinusitis
  • Acute pyelonephritis
  • Acute bacterial exacerbation of chronic bronchitis
  • Acute bacterial sinusitis.

A U.S. Food and Drug Administration (FDA) safety review found fluoroquinolones are associated with disabling side effects involving tendons, muscles, joints, nerves and the central nervous system. These side effects can occur hours to weeks after exposure to the drugs and may potentially be permanent, according to the agency. For that reason, the FDA has announced that patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections should only use fluoroquinolones when no alternative treatment options exist.

As with other antibacterial drugs, fluoroquinolones do not treat viral infections such as colds, flu or bronchitis in people who are otherwise healthy. They should be used “only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria,” according to the drug’s label. This is to reduce the development of drug-resistant bacteria and to maintain the effectiveness of fluoroquinolones and other antibacterial drugs.

Types of Fluoroquinolones

Six fluoroquinolones are currently available in the U.S. They can be administered in pills, injections and topical creams. Generally, fluoroquinolones are broken down into two categories: the older group (ciprofloxacin, norfloxacin, ofloxacin) and the newer group (gemifloxacin, levofloxacin, and moxifloxacin).

The most popular drugs in the class are:

  • Cipro and Cipro XR (ciprofloxacin)
  • Avelox (moxifloxacin)
  • Levaquin (levofloxacin)

Other fluoroquinolones exist such as Floxin (ofloxacin) and Factive (gemifloxacin) but are not as widely used. Maxaquin (lomefloxacin), Raxar (grepafloxacin hydrochloride) and Zagam (sparfloxacin) are no longer available in the U.S. Noroxin (norfloxacin) was discontinued by its manufacturer, Merck.

Cipro, Cipro XR, Proquin XR (ciprofloxacin) Uses & Dosages

Cipro is the most widely used of all the fluoroquinolones, making up about 66 percent of all prescriptions each year. Some 21 million Americans take this drug annually. It was originally approved in 1987 and is a second-generation fluoroquinolone. Doctors often prescribe it to treat mild-to-moderate respiratory and urinary tract infections, but it also treats other conditions, including gonorrhea, infectious diarrhea and anthrax.

Cipro 500mg Tablet

Cipro comes in the following formulas and doses:

Oral Tablets: 100 mg, 250 mg, 500 mg and 750 mg
Extended-release tablets: 500 mg and 1,000 mg (available only as generic)
Intravenous: 200 mg to 400 mg

Levaquin (levofloxacin) Uses & Dosages

Levaquin is the second-most-popular drug in the class, accounting for more than 28 percent of all prescriptions. It is a third-generation fluoroquinolone, originally approved in 1996. In 2010, it was the best-selling antibiotic in the U.S. Like Cipro, it treats respiratory and urinary tract infections. It also treats other conditions, including plague, anthrax, bronchitis and pneumonia.

Levaquin 750mg Tablet

Levaquin comes in the following formulas and doses:

Oral Tablets: 250 mg, 500 mg and 750 mg
Intravenous: 500 mg

Avelox (moxifloxacin) Uses & Dosages

The third-most-popular fluoroquinolone in the U.S. is Avelox, a fourth-generation medication. The number of Avelox prescriptions dropped 78 percent from 2.7 million prescriptions in 2010 to 609,000 prescriptions in 2014. The FDA approved the drug in 1999 to treat multi drug-resistant types of Streptococcus pneumoniae – bacteria that cause pneumonia, ear infections and meningitis, among other conditions. It also treats skin infections, cellulitis and intra-abdominal infections.

Avelox 400mg Tablet

Avelox comes in the following formulas and doses:

Oral Tablets: 400 mg
Intravenous: 400 mg

Other Fluoroquinolones

Factive and Floxin account for about .0005 percent of the total number of prescriptions for the class. Noroxin, Maxaquin, Raxar and Zagam are no longer on the market in the U.S.

  • Factive — available in 320mg tablets and treats chronic bronchitis and pneumonia.
  • Floxin — available in 200, 300 and 400mg tablets. This drug is more toxic than others in its class and often causes adverse events in patients.
  • Noroxin — discontinued in 2014 for unclear reason. It was available in 400mg tablets to treat sexually transmitted diseases and urinary tract infections.
  • Maxaquin — no longer available in the U.S., though it may still be used in generic versions.
  • Raxar — withdrawn from the market in 1999 because it was shown to cause adverse cardiac events.
  • Zagam — withdrawn from the market in 2001 because of phototoxicity and cardiac events.

Side Effects of Cipro, Levaquin and Avelox

Over the years, the FDA has received reports of life-changing adverse events in patients who have taken fluoroquinolone antibiotics. The most severe side effects of fluoroquinolones are considered rare. Some can be fatal. Common side effects of fluoroquinolones include headaches, lightheadedness, nausea, diarrhea, dizziness and trouble sleeping.

Potential serious side effects involving, tendons, muscles, joints, nerves, the central nervous system, the heart and other body systems include:

  • Swelling or inflammation of the tendons
  • Tendon rupture
  • Tingling or pricking sensation (“pins and needles”)
  • Numbness in arms or legs
  • Muscle pain
  • Joint pain or swelling
  • Depression
  • Hallucinations
  • Suicidal thoughts
  • Confusion
  • Anxiety
  • Abnormally rapid or irregular heartbeat
  • Ringing or buzzing in the ears
  • Vision problems
  • Skin rash
  • Sensitivity of skin to sunlight
  • Fatigue
  • Worsening of myasthenia gravis
  • Aortic aneurysm
  • Aortic dissection

Black Box Warnings

When the FDA determines that an approved drug carries significant risks, the agency requires that drug manufacturers add a black box warning to the product. This allows both doctors and users to become aware of the risks associated with using the medication. A black box warning is a serious step — just one away from removing a medication from the shelves.

Studies show people who have taken fluoroquinolones to treat infections may be at risk for developing life-altering side effects such as tendon problems, deadly heart conditions and permanent nerve damage. The FDA has added and enhanced black box warning information to fluoroquinolone labels since 2008 as new risks have come to light.

  • July 2008

    The FDA concluded that fluoroquinolones are associated with tendinitis and tendon rupture. The agency notified drug makers that they needed to add a warning to all fluoroquinolone medication information, outlining the increased risk of developing these conditions.

  • February 2011

    The FDA added to the black box warning the risk of worsening symptoms of myasthenia gravis, a long-term neuromuscular disease that leads to varying degrees of muscle weakness.

  • August 2013

    The FDA added a warning to fluoroquinolone labels for a form of permanent nerve damage called peripheral neuropathy.

  • July 2016

    Following a 2015 FDA advisory committee meeting where experts discussed the dangers of fluoroquinolones, the FDA added another warning. In May 2016, the agency had advised doctors to avoid using fluoroquinolones in patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections that can be cured with other medications. In July, the FDA mandated this labeling addition.

Other Problems Associated with Fluoroquinolone Antibiotics

Due to the expanding number and severity of fluoroquinolone-related problems, medical professionals can now diagnose Fluoroquinolone-Assisted Disability (FQAD) in patients. Individuals with FQAD are defined as U.S. patients who were reported to be previously healthy and have suffered debilitating side effects from fluoroquinolone use. What’s more, FQAD sufferers are patients who have been given fluoroquinolones when their conditions could have been cured with a far less powerful medication.

The diagnosis of FQAD was established in order to organize the diverse list of problems that can result from using these drugs. In addition to aortic aneurysm and peripheral neuropathy, the list of problems that can result from taking fluoroquinolones includes kidney disease and toxicity. What’s worse, the FDA has published safety alerts, notifying the public that the drugs are over-prescribed and are too risky for certain uses.

Over-Prescribing Fluoroquinolones

In 2013, the FDA released a Safety Communication warning about over-prescribing  fluoroquinolones and said current warnings were not clear enough. Specifically, the agency said “the potential rapid onset and risk of permanence were not adequately described,” and the “permanent damage among patients exposed to these medications cannot be calculated.” Then in 2016, the FDA announced that fluoroquinolones were too risky for use in minor infections such as uncomplicated urinary tract infections. However, many doctors have not updated their prescribing practices accordingly, and some researchers say fluoroquinolones are still over-prescribed for minor issues like earaches and sinusitis.


Doctors Speak on Fluoroquinolones

Infectious disease physician Dr. Lindsey R. Baden told Consumer Reports that doctors tend to overprescribe fluoroquinolones because the drugs are effective against many bacteria.

Dr. Mahyar Etminan, an epidemiologist at the University of British Columbia, told The New York Times that overusing these drugs is like “trying to kill a fly with an automatic weapon.”

Dr. Jay S. Cohen, an author and professor of psychiatry who discussed preventing medication side effects, spent years detailing the dangers of fluoroquinolones, which he called the “worst medication disaster in U.S. history.”


Kidney Disease

In a 2013 study, American and Canadian researchers teamed up to explore the risk of kidney disease in users of fluoroquinolone antibiotics. They found the risk of acute kidney injury is doubled in people who have used fluoroquinolones, especially ciprofloxacin and moxifloxacin. This condition requires hospitalization and often involves expensive renal care and multiple follow-up visits.

Toxicity

These drugs have also been linked to fluoroquinolone toxicity. This uncommon condition occurs in people who have adverse reactions to even small amounts of fluoride, a primary building block of fluoroquinolones. Toxicity is often detected when patients visit their doctors and complain about musculoskeletal symptoms such as hip pain that worsens with movement. There is no medically recognized syndrome associated with fluoroquinolone toxicity.

Author

emiller@drugwatch.com
407-955-4198

Emily Miller holds five Health Literacy certificates from the Centers for Disease Control and Prevention as well as a Bachelor of Science in Journalism from the University of Florida. She is a member of The Alliance of Professional Health Advocates and the American Association for the Advancement of Science. Emily was diagnosed with a chronic illness as a child and has firsthand experience with many of the topics she writes about as a member of the Drugwatch team. She is an award-winning journalist who has reported on health and legal news for reputable organizations, including the South Florida Sun Sentinel, San Antonio Express-News, UF Health News and Reporters Committee for Freedom of the Press. She draws on her background as both a patient and a journalist to help readers understand complex health and legal topics.


Hide Sources

  1. Brody, J. E. (2012, September 10). Popular antibiotics may carry serious side effects. Retrieved from http://well.blogs.nytimes.com/2012/09/10/popular-antibiotics-may-carry-serious-side-effects/?_r=0
  2. U.S. Food and Drug Administration. (2016, July 26). FDA updates warnings for fluoroquinolone antibiotics. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513183.htm
  3. American Society of Health-System Pharmacists. (2014, April 29). Norfloxacin Tablets (Noroxin). Retrieved from http://www.ashp.org/menu/DrugShortages/DrugsNoLongerAvailable/bulletin.aspx?id=1099
  4. FDA.gov. (2008, July 8). Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]. Retrieved from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126085.htm
  5. FDA.gov. (2013, August 15). FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. Retrieved from http://www.fda.gov/Drugs/DrugSafety/ucm365050.htm
  6. FDA.gov. (2016, May 12). FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Retrieved from http://www.fda.gov/drugs/drugsafety/ucm511530.htm
  7. Lee, C. & et al. (2015, November). Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone. Retrieved from http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2451282
  8. ScienceDaily.com. (2013, June 3). Risk of kidney disease doubled with use of fluoroquinolone antibiotics. Retrieved from https://www.sciencedaily.com/releases/2013/06/130603135311.htm
  9. U.S. Food and Drug Administration. (2013, August 15). FDA drug safety communication. Retrieved from http://www.fda.gov/downloads/Drugs/DrugSafety/UCM365078.pdf
  10. Etminan, M., Brophy, J. M., & Samii, A. (2014, August 22). Oral fluoroquinolone use and risk of peripheral neuropathy. Retrieved from http://www.neurology.org/content/83/14/1261.short
  11. U.S. Food and Drug Administration. (2015, November 5). FDA briefing document. Retrieved from http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm467383.pdf
  12. Carr, T. (2016, May 16). Fluoroquinolones too risky for common infections. Retrieved from http://www.consumerreports.org/drugs/fluoroquinolones-are-too-risky-for-common-infections/
  13. Strauchman, M., & Morningstar, M. W. (2012, October 12). Fluoroquinolone toxicity symptoms in a patient presenting with low back pain. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981197/
  14. Grill, M. F., & Maganti, R. K. (2011, September). Neurotoxic effects associated with antibiotic use: management considerations. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175508/
  15. Wiley, F. (2015, October 19). Antibiotics: Warnings, precautions, side effects & interactions. Retrieved from http://www.everydayhealth.com/antibiotics/guide/
  16. Horn, J. R., & Hansten, P.D. (2016, April 11). Fluoroquinolones and steroids: An Achilles heel interaction. Retrieved from ttp://www.pharmacytimes.com/publications/issue/2016/april2016/fluoroquinolones-and-steroids-an-achilles-heel-interaction
  17. Bird, S.T. (2013, July 9). Risk of acute kidney injury associated with the use of fluoroquinolones. Retrieved from http://www.cmaj.ca/content/185/10/E475.short
  18. FDA.gov. (2001, October 30). CIPRO (Ciprofloxacin) Use by Pregnant and Lactating Women. Retrieved from http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130712.htm
  19. FDA.gov. (1999, November 1). Withdrawal of Product: RAXAR( (grepafloxacin HCl) 600 mg Tablets, 400 mg Tablets, and 200 mg Tablets. Retrieved from https://www.fda.gov/ohrms/dockets/ac/00/backgrd/3634b1a_tab5b.htm
  20. Daneman, N. et al. (2015). Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ. Retrieved from http://bmjopen.bmj.com/content/5/11/e010077.full
  21. Boyles, S. (2015, October 7). Fluoroquinolones May Increase Aortic Aneurysm Risk. MedPage Today. Retrieved from http://www.medpagetoday.com/Cardiology/Prevention/53950
  22. Lee, C. et al. (2015). Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone. JAMA. Retrieved from http://archinte.jamanetwork.com/article.aspx?articleid=2451282
  23. Transparency Market Research. (2014). Antibacterial drugs market to top $45B globally in 2019. Retrieved from http://www.centerwatch.com/news-online/article/6094/antibacterial-drugs-market-to-top-45b-globally-in-2019#sthash.IpNjLglz.dpbs
  24. U.S. National Library of Medicine. (2015). Fluoroquinolones. LiverTox. Retrieved from http://livertox.nih.gov/Fluoroquinolones.htm
  25. Centers for Disease Control and Prevention (CDC). (2010). Quinilones and the Clinical Laboratory. Retrieved from http://www.cdc.gov/HAI/settings/lab/Quinolones-Clinical-Laboratory.html
  26. Etminan, M. et al. (2014). Oral fluoroquinolone use and risk of peripheral neuropathy. Neurology. Retrieved from http://www.neurology.org/content/83/14/1261.short
  27. Brody, J.E. (2012, September 10). Popular antibiotics may carry serious side effects. The New York Times. Retrieved from http://well.blogs.nytimes.com/2012/09/10/popular-antibiotics-may-carry-serious-side-effects/?_r=0
  28. Creative Commons. (n.d.). Cipro CR. Retrieved from https://pillbox.nlm.nih.gov/assets/large/680840070.jpg
  29. Creative Commons. (n.d.). Levaquin. https://pillbox.nlm.nih.gov/assets/large/50458-0930-20_3E161F70.jpg
  30. Creative Commons. (n.d.). Avelox. https://pillbox.nlm.nih.gov/assets/large/00085-1733-03_SPLIMAGE30_2619935C.jpg
  31. National Institute of Neurological Disorders and Stroke. (n.d.). Peripheral Neuropathy Fact Sheet. Retrieved from https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Peripheral-Neuropathy-Fact-Sheet
Free Cipro, Levaquin and Avelox Case Review

Did you experience aortic complications after taking fluoroquinolones?
Free Case Review